The subcellular distribution of (3H)-styrene-7,8-oxide was studied in the rat liver. The compound was added to liver homogenate to give a final concentration of 2 times 10−5; 2 times 10−4 and 2 times 10−3 M. Subcellular fractions were obtained by differential centrifugation. Most of styrene oxide (59-88%) was associated with the cytosolic fraction. Less than 15 percent of the compound was retrieved in each of the nuclear, mitochondrial and microsomal fractions. A considerable percentage of radioactivity was found unextractable with the organic solvents, suggesting that styrene oxide reacted with the endogenous compounds. The intracellular distribution of this epoxide was also studied in the perfused rat liver. Comparable results with those previously described were obtained. The binding of styrene oxide to the cytosolic protein was investigated by equilibrium dialysis and ultrafiltration. Only a small percentage of the compound was bound to protein.
References
1.
1. Maltoni C, Failla G, Kassapidis G (1979). First experimental demonstration of carcinogenic effects of styrene oxide. Med. Lav.5:358–362.
2.
2. Kankaanpää ITJ. Hemminki K, Vainio H (1979). Embryotoxicity and teratogenicity of styrene and styrene oxide on chick embryos enhanced by trichloropropylene oxide. Acta Pharmacol. Toxicol.45:399–402.
3.
3. Bend JR, Smith BR, Van Anda J, Ryan AJ, Fouls JR (1978). Biotransformation of styrene oxide by the isolated perfused rat liver and by subfractions of homogenized liver cells. Excerpta Med. Int. Congr. Ser.440:62–70.
4.
4. Pacifici GM, Linberg B, Glaumann H, Rane A (1984). Styrene oxide metabolism in rhesus monkey liver: enzyme activities in the subcellular fractions and in isolated hepatocytes. J. Pharmacol. Exp. Ther.226:869–875.
5.
5. Pacifici GM, Colizzi C, Giuliani L, Rane A (1983): Nuclear epoxide hydrolase in the human fetal and adult liver. Pharmacology, (In Press)
6.
6. Pacifici GM, Colizzi C, Giuliani L, Rane A (1983). Cytosolic epoxide hydrolase in fetal and adult human liver. Arch. Toxicol.54:331–341.
7.
7. Pacifici GM (1983): Epoxide detoxication pathways in the human fetus. Academic Dissertation in Clinical Pharmacology, Karolinska Institute, Sweden.
8.
8. Ng DS, Maickel RP, Borowitz JL (1982). Subcellular distribution of weak acids and bases in adrenal medulla. Gen. Pharmacol.13:15–20.
9.
9. Manara L, Mennini T, Cerletti C (1974). 3H-Reserpine persistently bound in vivo to rat brain subcellular components: limited removal by peanut oil extraction. Life Sci.14:2267–2276.
10.
10. Cerletti C, Coccia P, Manara L, Mennini T, Recchia M (1978). Subcellular distribution of ethorphine in rat brain and evidence for in viva stereospecific binding. Br. J. Pharmacol.62:31–38.
11.
11. Marafino BJ, Giri SN, Siegel DM (1981). Pharmacokinetics, covalent binding and subcellular distribution of 3H-doxorubicin after intravenous administration in the mouse. J. Pharmacol. Exp. Ther.261:55–61.
12.
12. Pacifici GM, Rane A (1982). Metabolism of styrońe oxide in different human fetal tissues. Drug Metab. Disp.10:302–305.
13.
13. Van Anda J, Smith BR, Fouls JR, Bend JR (1979). Concentration-dependent metabolism and toxicity of 14C-styrene oxide in the isolated perfused rat liver. J. Pharmacol. Exp. Ther.211:207–211.
14.
14. Jerina DM, Dansette PM, Lu AYH, Levin W (1977). Hepatic microsomal epoxide hydratase: a sensitive radiometric assay for hydration of arene oxides of carcinogenic hydrocarbons. Mol. Pharmacol.13:342–351.
15.
15. Ross BD (1972): Perfusion Techniques in Biochemistry. Clarendon Press, pp 165–175.
16.
16. Lowry OH, Rosebrough NJ, Farr AL. Randall RJ (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem.193:265–275.
17.
17. Turner JC (1969). Tritium counting with Triton x-100 scintillant. Int. J. Appl. Radiat. Isotop.20:499–505.
18.
18. La Du BN, Mandel HG, Way EL (1971): Fundamentals of Drug Metabolism and Drug Disposition. The Williams & Wilkins. Company, Baltimore.
19.
19. Choie DD, Del Campo AA, Guarino AM (1980). Subcellular localization of cis-dichlorodiamine-platinum (II) in rat kidney and liver. Toxicol. Appl. Pharmacol.55:245–252.
20.
20. Uszynski M, Malofiejew M (1971). Subcellular distribution of 8-14C-mescaline in the mouse brain and liver. Biochem. Pharmacol.20:3207–3210.
21.
21. Dunphy WG, Kochenburger RJ, Castagna M, Blumberg PM (1981). Kinetics and subcellular localization of specific 3H-Phorbol-12,13-dibutyrate binding by mouse brain. Cancer Res.41:2640–2647.
22.
22. Beeler JT, Schibeci A, Martonosi A (1980). The binding of arsenazo III to cell components. Biochim. Biophys. Acta629:317–327.
23.
23. Marzo A, Ghirardi P, Preti A, Lombardo A, Longhini C, Musacci G (1972). Subcellular distribution of deslanatoside C, ouabain and digitoxin in the heart and liver of conscious guinea pigs. Biochem. Pharmacol.26:2427–2431.
24.
24. Colburn RW, Ng LKY, Lemberger LL, Kopin IJ (1974). Subcellular distribution of tetrahydrocannabinol in rat brain. Biochem. Pharmacol.23:873–877.
25.
25. Dutta S, Marks BH, Stephen PM (1976). The uptake and subcellular distribution of radiolabelled metabolites of digitoxin in the guinea-pig isolated perfused heart. Br. J. Pharmacol.56:437–441.
26.
26. Ota K, Hammock BD (1980). Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science207:1479–1481.
27.
27. Gill SS, Hammock BD (1980): Distribution and properties of mammalian soluble styrene oxidehydroxylase. Biochem. Pharmacol.29:389–395.
28.
28. Hosegawa LS, Hammock RD (1982). Spectrophotometric assay for mammalian cytosolic epoxide hydrolase using trans-stylbene oxide as the substrate. Biochem. Pharmacol.31:1979–1984.
